{"id":"W4395664784","doi":"10.1097/hc9.0000000000000426","title":"Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial","year":2024,"lang":"en","type":"article","venue":"Hepatology Communications","topic":"Liver Diseases and Immunity","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network","funders":"Medical Research Council; Ipsen; Department of Health and Social Care; Cancer Research UK; Wellcome Trust; Health and Social Care Research and Development Division; Novo Nordisk; National Institute for Health and Care Research; Regeneron Pharmaceuticals; Pfizer; National Institute for Social Care and Health Research; Gilead Sciences; GlaxoSmithKline; Birmingham Biomedical Research Centre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Primary sclerosing cholangitis; Blockade; Medicine; Fibrosis; Adhesion; Monoclonal antibody; Gastroenterology; Internal medicine; Biliary tract; Liver fibrosis; Antibody; Pathology; Immunology; Disease; Receptor; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003827243,0.000185286,0.0004145384,0.0002266683,0.000450853,0.0001063736,0.0008698106,0.0001618103,0.0001150213],"category_scores_gemma":[0.0001762285,0.0001794506,0.0001035962,0.0004199064,0.0002448042,0.00034025,0.001389907,0.0006570673,0.00006581374],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002628701,"about_ca_system_score_gemma":0.0003483896,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004646093,"about_ca_topic_score_gemma":0.00005050521,"domain_scores_codex":[0.9982373,0.0004898293,0.0004986512,0.0003157739,0.0001554768,0.0003030017],"domain_scores_gemma":[0.9976072,0.0001819797,0.00008071116,0.001904493,0.00008725212,0.0001383129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.03838636,0.2650325,0.01733118,0.002031734,0.002097527,0.0007011499,0.007614108,0.000001929876,0.5050384,0.006973324,0.00588064,0.1489111],"study_design_scores_gemma":[0.6491033,0.02375206,0.01249492,0.01058294,0.00282693,0.0004038317,0.001119975,0.03227825,0.01277372,0.001378243,0.2513291,0.001956724],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9758453,0.01404507,0.00006305054,0.003902107,0.0002153337,0.002508322,0.00004194461,0.0001731599,0.003205705],"genre_scores_gemma":[0.9930984,0.001325356,0.003826084,0.0005349593,0.00005373588,0.0004316709,0.000474964,0.0000379928,0.0002168657],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6107169,"threshold_uncertainty_score":0.7317784,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1235209284734993,"score_gpt":0.3727805712484096,"score_spread":0.2492596427749103,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}